Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Clinical trial NCT02972333 · UNKNOWN

Trial details

NCT number: NCT02972333
Sponsor: Shandong Cancer Hospital and Institute
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

EGFR-TKI Resistant Mutation Nonsmall Cell Lung Cancer AZD9291 Brain Metastases

Start date: 2016-12-01
Primary completion: 2019-09-01
Enrollment: 150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.